Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03839446
Title Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael Boyiadzis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field